Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC07-523LS, PGT121.414.LS, and PGDM1400LS in Adults Without HIV
NCT06812494Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of VRC07-523LS, PGT121 and PGDM1400LS in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and Percentage of Participants Experiencing Local Adverse Events at Day 173, Number and Percentage of Participants Experiencing Systemic Adverse Events at Day 173 and 6 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
VRC07-523LSPGT121PGDM1400LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06812494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812494.